

First Author,	Main Study Findings						
Publication Year	DOD (04) DDD (040)						
Wadei ¹⁰ 2013	DCD (n = 64) vs DBD (n = 248) adjusted analysis (covariates not specified)						
	Delayed graft function RR 1.66; 95% CI, 1.02 to 2.71; <i>P</i> = 0.041						
	Biopsy proven rejection RR 1.32; 95% CI, 0.71 to 2.45; <i>P</i> = 0.39						
	Death-censored graft loss or two consecutive iGFRs<50 RR 1.16; 95% CI, 0.68 to 1.97; $P = 0.59$						
	Graft loss or death RR 1.09; 95% CI, 0.58 to 2.06; <i>P</i> = 0.79						
	Death RR 0.97; 95% CI, 0.41 to 2.27; <i>P</i> = 0.94						
Nagaraja ⁶ 2012	All recipients [DCD (n = 80) vs DBD (n = 226)] (unadjusted analysis)						
2012	Delayed graft function						
	73% vs 27%; P<0.001						
	Primary non-function						
	1 (1.3%) vs, 5 (2.2%), p=0.6						
	Biopsy proven acute rejection 9% vs 23%; <i>P</i> <0.001						
	1 year/4 year graft survival 94% vs 90% / 79% vs 82% <i>P</i> = 0.44						
	4 year death-censored graft survival 95% vs 91%; $P = 0.26$						
	Patient survival						
	No significant difference between groups, $P = 0.9$						
Bellingham ¹¹ 2011	DCD (n = 965) vs DBD (n = 2674) (unadjusted analysis)						
	delayed graft function						
	35.7% vs 20.3% ; $P \le 0.0001$						
	Era 1980-1992 1993-2008						
	DCD DBD DCD DBD						
	Delayed graft function (%)						
	30 16 45 22						
	Free of acute cellular rejection (%)*						

CADTH RAPID RESPONSE SERVICE

First Author,	Main Study Findings								
Publication Year									
	1 year	33	50	70	66				
	3 year	30	46	67	61				
	10 year	26	41	58	55				
	P value ≤0.001 0.07								
	Graft survival (%)								
	1 year	72	83	87	89				
	3 year	63	74	77	78				
	10 year 38 40 47 46 P value 0.04 0.47 Patient survival (%)								
	1 year	92	95	93	95				
	3 year	84	89	86	88				
	10 year	60	57	57	63				
	P value		.58	0.	.06				
7	*Rejection was biopsy pro								
Pine ⁷ 2010	DCD (n = 103) vs DBD (r (unadjusted analysis: pati		chad on r	ociniont a	nd donor a	ao			
2010	sex, and BMI; HLA misma								
	regimen)	alci ies, is	cri c iiia iii	ne, iiiiiiu	nosuppres	SIVE			
	regimen)								
	Delayed graft function								
	58% vs 28%, P = 0.03								
	3070 VS 2070, F = 0.03								
	Primary non-function								
	4% vs 1%, <i>P</i> = 0.04								
	·								
	Biopsy proven acute reject	ction							
	12% vs 16%, P = NS								
	1 year/3 year graft surviva								
	97% vs 96% / 85% vs 869	%, P = 0.3	30						
	1 year / 3 year recipient s		40						
Cinab ¹²	98% vs 97% / 92% vs 959			d opolycio	\				
Singh ¹² 2011	DCD (n = 70) vs DBD (n	= ၁၀၀) (0	maujustet	a analysis)				
2011	Delayed graft function								
	40 (57%) vs 109 (21%); F	P = 0.000	1						
	10 (07 70) \$3 100 (21 70), 1	_ 5.555	•						
	Biopsy-proven acute reject	ction							
	20 (29%) vs 82 (16%); <i>P</i> = 0.018								
	Overall graft survival								
	54 (77%) vs 402 (79%); NS								
	Death-censored graft loss								
	10 (15%) vs 68 (13%); NS								

First Author,	Main Study Findings
Publication Year	
	Overall patient survival
2 " 3 2 2 4 2	62 (89%) vs 456 (90%); NS
Snoeijs ³ 2010	DCD vs DBD
	Adjusted analysis (patients matched on transplant type, year and other key characteristics)
	Delayed graft function (N = 726) OR 10.3; 95% CI, 6.68 to 15.9; <i>P</i> < 0.001
	Primary non function (N = 811) OR 7.51; 95% CI, 4.01 to 14.1; <i>P</i> < 0.001
	Death-censored graft loss at 15 years (N = 851) HR 1.82; 95% CI, 1.37 to 2.42; <i>P</i> < 0.001
	Patient survival at 15 years (N = 857) HR 1.16; 95% CI, 0.87 to 1.54; P = 0.32
	eGFR at 1 year (N = 646)
	mean difference -6.2 mL/min; 95% CI, -9.4 to -3.0); <i>P</i> <0.001
Snoejis ¹³ 2010	DCD (n = 459) vs DBD (n = 680)
	Graft failure in first 3 months (unadjusted) 12.0% vs 6.3%; $P = 0.001$
	Mortality rate, % per patient-year (unadjusted) DCD 3.4% vs DBD 3.7% vs dialysis 5.0%, <i>P</i> value not reported
	Mortality rate (adjusted analysis) Standard criteria DBD vs dialysis treatment HR 0.51; 95% CI, 0.32 to 0.81; $P = 0.004$
	Standard criteria DCD vs conventional therapy† HR 0.44; 95% CI, 0.24 to 0.80; $P = 0.007$
	Extended criteria* DBD vs conventional therapy† HR 1.12; 95% CI, 0.71 to 1.76; $P = 0.62$
	Extended criteria* DCD vs conventional therapy† HR 0.61; 95% CI, 0.31 to 1.19; $P = 0.15$
	†conventional therapy defined as dialysis treatment or waiting on dialysis until standard criteria DBD transplantation (follow up continued after receipt of DBD kidney)
	*extended criteria donors were ≥60 years or between 50 and 60 years

First Author,	Main Study Findings						
Publication Year	with two additional risk factors (elevated creatinine, hypertension or						
				eatinine, hype	rtension or		
C	cardiovascular cause of death)						
Summers ⁸ 2010	DCD vs DBD for all transplant recipients						
2010	(unadjusted)						
	Delayed graft function						
	332/659 (50%) vs 1386/5474 (25%); P < 0.0001						
	Acute rejection in first 3 months						
	121/723 (17%) vs 1646/6793 (24%); P < 0.0001						
	DCD (n = 739) vs DBD (n = 6759) for first transplant recipients						
	Graft failure up to 5 years (adjusted)						
Barlow ⁹	HR 1.01; 95% CI, 0.83 to 1.19; <i>P</i> = 0.97						
2009	NHBD (n = 112) vs HBD (n = 164)						
2009	(unadjusted analysis; patients matched for cold ischemia time, HLA mismatches, donor age, prior transplant and 2 of 4 minor criteria)						
	mismatories, donor age, prior transplant and 2 of 4 millor criteria)						
	Delayed graft function						
	94 (83.9%) vs 36 (22.0%); <i>P</i> < 0.001						
	Primary non-function						
	6 (5.4%) vs 3 (1.8%); P = 0.164						
	Biopsy proven acute rejection						
	33 (29.5%) vs 63 (38.4%); <i>P</i> = 0.157						
		Death-censored graft Graft and patient survival					
	Veer	surviva		(%)†			
	Year	DCD 92	DBD 91	DCD 86	DBD 88		
	3	82	89	76	82		
	5	78	86	69	76		
	10	61	72	50	58		
	15	44	59	29	44		
	P value	0.0)52		22		
	*graft failures	are events; †g	raft failure or o	death are even	ts in these		
	time to event analyses						
	serum creatinine was significantly higher in NHBD recipients at 1 (P =						
	0.009), 2 ($P = 0.009$), 11 ($P = 0.038$), and 12 ($P = 0.010$) years and						
	not significantly different at all other time points (0.25 to 15 years).						

DBD = donation after brain death; DCD = donation after cardiocirculatory death; DCGL = death-censored graft loss; DCGS = death-censored graft survival; DGF = delayed graft function; eGFR = estimated glomular filtration rate; HBD = heart beating donor; HR = hazard ratio; NHBD = non-heart beating donor; NS = not significant; OR = odds ratio